利用药物重定位转录组学方法鉴定原发性干燥综合征的新候选药物
研究比较原发性干燥综合征(pSS)患者与健康对照的外周血转录组,在五个独立数据集中分析差异表达基因与Connectivity Map数据库中2837种药物、2160个敲入基因和3799个敲降基因的关联,鉴定出11种潜在候选药物,其中组蛋白去乙酰化酶和PI3K抑制剂关联最显著,并确认干扰素通路为关键靶点。
要点
- 11种药物为潜在候选药物,组蛋白去乙酰化酶和PI3K抑制剂关联最显著。
- 12个敲入基因与pSS样表达谱相关,23个敲降基因与pSS逆转表达谱相关。
- 28/35(80%)的相关基因受干扰素调控。
核心结论
- 这是SS中首个药物重定位转录组学方法,确认靶向干扰素的价值,并鉴定组蛋白去乙酰化酶和PI3K抑制剂为潜在治疗靶点。
研究设计与样本
- 研究比较pSS患者与健康对照的外周血基因表达,数据来自两个队列和三个公共数据库,共五个数据集。
- 在每个数据集中分析pSS患者与对照之间上调和下调最显著的150个基因,并与Connectivity Map数据库中2837种药物作用于9种细胞系、2160个敲入基因和3799个敲降基因所得的差异表达基因进行关联分析。
主要发现
- 共分析来自五项独立研究的1008份外周血转录组,包括868例pSS患者和140例健康对照。
- 11种药物为潜在候选药物,其中组蛋白去乙酰化酶和PI3K抑制剂关联最显著。
- 12个敲入基因与pSS样表达谱相关,23个敲降基因与pSS逆转表达谱相关。
- 这些基因中的大多数(28/35,80%)受干扰素调控。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To date, no immunomodulatory drug has demonstrated its efficacy in primary SS (pSS). We sought to analyse potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes. METHODS: Gene expression from peripheral blood samples of patients with pSS was compared with that of healthy controls in two cohorts and three public databases. In each of the five datasets, we analysed the 150 most up- and downregulated genes between pSS patients and controls with regard to the differentially expressed genes resulting from the biological action on nine cell lines of 2837 drugs, 2160 knock-in and 3799 knock-down genes in the Connectivity Map database. RESULTS: We analysed 1008 peripheral blood transcriptomes from five independent studies (868 patients with pSS and 140 healthy controls). Eleven drugs could represent potential candidate drugs, with histone deacetylases and PI3K inhibitors among the most significantly associated. Twelve knock-in genes were associated with a pSS-like profile and 23 knock-down genes were associated with a pSS-revert profile. Most of those genes (28/35, 80%) were interferon-regulated. CONCLUSION: This first drug repositioning transcriptomic approach in SS confirms the interest of targeting interferons and identifies histone deacetylases and PI3K inhibitors as potential therapeutic targets.
引用
- Felten R, Ye T, Schleiss C, et al. Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford). 2023. PMID: 36869684. doi:10.1093/rheumatology/kead096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。